Compare PSNL & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSNL | DNA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.8M | 607.1M |
| IPO Year | 2019 | N/A |
| Metric | PSNL | DNA |
|---|---|---|
| Price | $7.88 | $9.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $11.17 | $10.50 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 02-26-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $69,103,000.00 | ★ $180,606,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.41 | $3.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $5.00 |
| 52 Week High | $11.50 | $17.58 |
| Indicator | PSNL | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 55.80 |
| Support Level | $7.27 | $7.73 |
| Resistance Level | $9.79 | $10.23 |
| Average True Range (ATR) | 0.86 | 0.78 |
| MACD | -0.28 | -0.00 |
| Stochastic Oscillator | 14.89 | 64.69 |
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.